
Solid Biosciences SLDB
$ 8.39
4.61%
Annual report 2025
added 03-19-2026
Solid Biosciences Total Shareholders Equity 2011-2026 | SLDB
Annual Total Shareholders Equity Solid Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 180 M | 137 M | 126 M | 212 M | 208 M | 132 M | 80 M | 125 M | -59.3 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 212 M | -59.3 M | 127 M |
Quarterly Total Shareholders Equity Solid Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 218 M | 258 M | 294 M | 137 M | 167 M | 193 M | 211 M | 126 M | 144 M | 164 M | 184 M | 212 M | 143 M | 162 M | 186 M | 208 M | 223 M | 238 M | 253 M | 132 M | 132 M | 132 M | 132 M | 80 M | 80 M | 80 M | 80 M | 125 M | 125 M | 125 M | 125 M | -59.3 M | -59.3 M | -59.3 M | -59.3 M | -37.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 294 M | -59.3 M | 133 M |
Total Shareholders Equity of other stocks in the Drug manufacturers industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
17 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-808 K | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | ||
|
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
-6.6 B | - | - | $ 28.9 M | ||
|
DURECT Corporation
DRRX
|
14.8 M | - | - | $ 50.1 M | ||
|
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
-6.51 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B | ||
|
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
22.9 M | $ 3.12 | 0.97 % | $ 43.9 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
1.01 B | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
557 M | - | 2.45 % | $ 38.1 M | ||
|
Bausch Health Companies
BHC
|
-1.02 B | $ 5.72 | 2.14 % | $ 2.09 B | ||
|
Harrow Health
HROW
|
52.4 M | $ 37.1 | 3.26 % | $ 1.36 B | ||
|
Aurora Cannabis
ACB
|
2.13 B | $ 3.48 | 1.46 % | $ 86.3 M | ||
|
Canopy Growth Corporation
CGC
|
487 M | $ 1.08 | 2.86 % | $ 116 M | ||
|
OrganiGram Holdings
OGI
|
300 M | $ 1.42 | 1.43 % | $ 402 M | ||
|
Jupiter Wellness
JUPW
|
35 M | - | - | $ 33.6 M | ||
|
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | ||
|
Neoleukin Therapeutics
NLTX
|
265 M | - | - | $ 193 M | ||
|
Evolus
EOLS
|
-23.1 M | $ 4.33 | 1.41 % | $ 279 M | ||
|
Emergent BioSolutions
EBS
|
649 M | $ 8.24 | 3.52 % | $ 422 M | ||
|
Sundial Growers
SNDL
|
270 M | $ 1.37 | -3.52 % | $ 3.37 M | ||
|
Organogenesis Holdings
ORGO
|
263 M | $ 2.38 | - | $ 313 M | ||
|
Pacira BioSciences
PCRX
|
778 M | $ 24.06 | 1.13 % | $ 1.11 B | ||
|
PetIQ
PETQ
|
223 M | - | 1.64 % | $ 400 M | ||
|
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | ||
|
Relmada Therapeutics
RLMD
|
86.5 M | $ 7.38 | 1.23 % | $ 291 M | ||
|
Assertio Holdings
ASRT
|
94 M | $ 18.02 | - | $ 115 M | ||
|
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
49.4 M | $ 1.01 | 1.0 % | $ 50.4 M | ||
|
PLx Pharma
PLXP
|
35.7 M | - | -27.8 % | $ 2.56 M | ||
|
Tilray
TLRY
|
3.32 B | $ 6.72 | 2.28 % | $ 4.15 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 2.35 | 3.07 % | $ 2.92 M | ||
|
Veru
VERU
|
32.3 M | $ 2.38 | - | $ 321 M | ||
|
Viatris
VTRS
|
20.5 B | $ 13.83 | 2.67 % | $ 16.6 B | ||
|
cbdMD
YCBD
|
1.96 M | $ 0.75 | 9.54 % | $ 3.23 M | ||
|
Zomedica Corp.
ZOM
|
115 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
37 M | $ 0.94 | 3.31 % | $ 33.8 M | ||
|
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
22.7 M | $ 0.65 | 0.6 % | $ 2.79 M | ||
|
TherapeuticsMD
TXMD
|
26.9 M | $ 2.05 | -0.97 % | $ 23.7 M |